Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.

Inclusion Criteria:

• received a renal transplant, induction with Campath-1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone.

Exclusion Criteria:

• Recipients of HLA-identical living-donor renal transplants;
• PRA value >20% within 30 days of transplant;
• GFR <40ml/min;
• multi-organ transplant;